Camp4 Therapeutics Receives Authorization In The United Kingdom For Phase 1/2 Human Clinical Trial Of Cmp-002 In Patients With Syngap1-Related Disorder
CAMP•United Kingdom authorization for Cmp-002 trial
Sept 10 (Reuters) - CAMP4 Therapeutics Corp CAMP.O:
- CAMP4 Therapeutics receives authorization in the United Kingdom for phase 1/2 human clinical trial of Cmp-002 in patients with Syngap1-related disorder
- CAMP4 Therapeutics Corp - to initiate Cmp-002 clinical trial in Q4 2026
- CAMP4 Therapeutics Corp - submits regulatory filings in EU for Cmp-002 trial
